Raydiant Oximetry
Raydiant Oximetry is a clinical-stage medical device company developing Lumerah, a non-invasive fetal pulse oximeter that directly measures fetal oxygen saturation during labor to reduce unnecessary cesarean deliveries, serving hospital labor & delivery units in both developed and low/middle-income country markets.
- Company typePrivate
- Founded2019
- HeadquartersSan Ramon, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Raydiant Oximetry does
Raydiant Oximetry is a clinical-stage medical device company developing non-invasive fetal monitoring technology for use during labor and delivery. The company's lead product, Lumerah, is a fetal pulse oximeter that uses an investigational transvaginal sensor positioned on the fetus's cheek during active labor to directly measure fetal oxygen saturation — addressing a 50-year gap in which electronic fetal monitoring has relied exclusively on indirect fetal heart rate measurement. The underlying platform combines advanced biophotonics (near-infrared spectroscopy) with machine learning algorithms trained on time-series physiological waveforms, with four patent families protecting the core technology. Lumerah received FDA Breakthrough Device designation in 2022, and preclinical work indicates an 80% improvement in diagnostic accuracy versus current standard of care.
The company targets obstetrical providers and labor & delivery units in hospitals, with a stated dual-market strategy covering high-income countries (US hospitals) and low/middle-income countries (LMIC) supported by non-dilutive funding from the Bill & Melinda Gates Foundation and the NIH. Business model mechanics remain pre-commercial: revenue is intended to flow through direct enterprise sales of Lumerah hardware and consumables to hospitals, with potential future licensing arrangements. Clinical evidence is being built through three academic study sites — Eastern Virginia Medical School (35-patient Early Feasibility Study completed October 2025), Louisiana State University Health Shreveport (IDE Pilot Study launched November 2025, expanded to 30 patients), and University of Texas Medical Branch. In May 2025, Raydiant entered a joint development initiative with GE HealthCare to advance fetal oxygen saturation monitoring, signaling intent to integrate with incumbent fetal monitoring infrastructure.
The company has raised approximately $22.6M+ across equity rounds (Series A 2019, Series A2 2021, Series A3 Extension 2024) and non-dilutive grants (Ireland $3M, Gates $1M, NIH RADx Tech $750K), with a syndicate of women-focused venture investors and impact-oriented funds. Operations are run from San Ramon, CA, with a team of 11-50 across clinical, regulatory, R&D, manufacturing, and commercial functions, led by CEO Mike Nagel (appointed September 2025) to drive the transition into device commercialization.
Raydiant Oximetry firmographics
Firmographics- Name
- Raydiant Oximetry
- Legal name
- Raydiant Oximetry, Inc.
- Website
- https://raydiantoximetry.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Raydiant Oximetry is a clinical-stage medical device company developing Lumerah, a non-invasive fetal pulse oximeter that directly measures fetal oxygen saturation during labor to reduce unnecessary cesarean deliveries, serving hospital labor & delivery units in both developed and low/middle-income country markets.
- Ownership category
- akta.pro rank
Raydiant Oximetry industry classification
Industry- Product category
- Fetal Monitoring Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF)
- akta.pro secondary industries
- Maternal, Neonatal & Pediatric Remote Monitoring (HLACAPAG), Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
Keywords
Where Raydiant Oximetry is headquartered
LocationHeadquarters
- HQ city
- San Ramon
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Raydiant Oximetry business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Raydiant Oximetry is a clinical-stage medical device company that does not yet have commercial revenue. Once regulatory approval is obtained, the company plans to generate revenue through the sale of its Lumerah fetal pulse oximeter devices and related consumables to hospitals and healthcare systems.
- Potential Licensing: Given the FDA Breakthrough Device status and patent protection, the company may pursue licensing arrangements for its technology platforms in the future.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Raydiant Oximetry product offering
Product offeringCore offering
Raydiant Oximetry is a clinical-stage medical device company developing Lumerah, a non-invasive fetal pulse oximeter that directly measures fetal oxygen saturation levels during active labor via an investigational transvaginal sensor placed on the fetus's cheek. The technology is designed for obstetrical providers and labor & delivery units in hospitals to reduce unnecessary cesarean deliveries and improve maternal and neonatal outcomes. Once FDA approval is obtained, the company plans to sell the Lumerah device and related consumables to hospitals and healthcare systems globally.
Product overview
Raydiant Oximetry is a clinical-stage medical device company developing fetal monitoring innovations through advanced biophotonics and machine learning. The company's primary product is Lumerah, a noninvasive fetal pulse oximeter that directly measures fetal oxygen levels during labor—addressing a 50-year gap where electronic fetal monitoring has relied on indirect fetal heart rate measurement. The technology aims to reduce the rising maternal and neonatal mortality and morbidity rates and the high rate of unnecessary cesarean deliveries driven by false positive fetal distress alerts. The company is pursuing both high-income and low/middle-income country markets, supported by grants from the Bill & Melinda Gates Foundation and NIH.
Differentiator
Problem solved
Functional benefit
Brands
- Lumerah: Non-invasive fetal pulse oximeter technology for measuring fetal oxygen saturation during labor to improve childbirth outcomes and reduce unnecessary C-sections.
Products and services
- Lumerah A non-invasive fetal pulse oximeter that directly measures fetal oxygen saturation levels during labor using an investigational transvaginal sensor positioned on the fetus's cheek, combined with advanced biophotonics and machine learning algorithms. Designed for obstetrical providers and labor & delivery units in hospitals to improve obstetric decision-making and reduce unnecessary cesarean deliveries.
- Daisy Surgical Device A surgical device under development for maternal and fetal care applications aimed at improving childbirth outcomes, being advanced alongside the Lumerah fetal pulse oximetry technology.
Quantifiable outcome
- Fetal pulse oximetry has been shown to reduce C-section rates for suspected fetal distress by 50%
- +3 more outcomes
Companies that use Raydiant Oximetry
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Raydiant Oximetry technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Raydiant Oximetry partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- GE HealthCarecoreAnnounced a joint development initiative in May 2025 to enhance fetal monitoring capabilities, leveraging combined expertise and technology to advance fetal oxygen saturation monitoring technology and strengthen clinical decision-making during labor.
- Eastern Virginia Medical SchoolcoreConducted a 35-patient Early Feasibility Study evaluating Lumerah fetal pulse oximetry technology to improve fetal monitoring during labor.
- Louisiana State University Health ShreveportcoreClinical study site for IDE Pilot Study using investigational transvaginal sensor for fetal pulse oximetry during active labor. Completed enrollment of first 15 patients with FDA approval to expand to 30 patients.
- University of Texas Medical BranchcoreClinical study site for planned studies of non-invasive fetal monitoring technology using Series A2 funding.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Raydiant Oximetry competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: Dominant incumbent in fetal and maternal monitoring (incl. Novii wireless patch system) and also Raydiant's joint development partner. Highly comparable as it sells fetal monitoring hardware into the same hospital L&D buyers Raydiant targets, and its commercial scale dwarfs Raydiant's.
- Philips (Avalon Fetal Monitors): Major incumbent with its Avalon series of external fetal monitoring products sold globally to hospitals and OB/GYN practices. Comparable as a primary alternative purchase for hospital L&D units evaluating Raydiant's Lumerah.
- Masimo: Pulse oximetry technology leader whose core expertise in SpO2 sensors and signal processing maps directly onto Raydiant's biophotonics approach. Could plausibly enter fetal pulse oximetry given engineering depth and OEM hospital relationships.
- Medtronic: Diversified medical device incumbent with patient monitoring and hospital capital equipment franchises. Relevant as a broad incumbent with resources to enter adjacent fetal monitoring categories and the relationships to displace a startup like Raydiant.
Direct peers
- Neoventa Medical: Direct peer in intrapartum fetal monitoring, commercializing STAN (ST analysis) methodology alongside fetal ECG to better detect fetal distress during labor. Targets the same clinical decision-making problem Raydiant aims to solve.
- PeriGen: AI-powered perinatal clinical decision support platform used in hospital labor & delivery units. Comparable as a software/data-driven approach to reducing unnecessary C-sections and improving obstetric outcomes — the same value proposition Raydiant's Lumerah targets.
- Huntleigh Healthcare: Established manufacturer of fetal monitoring dopplers, CTG, and obstetric ultrasound equipment sold to hospitals globally. Comparable as a direct alternative supplier of fetal monitoring hardware to the same L&D buyers Raydiant targets.
Emerging players
- Nuvo Group (Invu platform): Emerging remote maternal-fetal monitoring platform with a remote-prescription wearable for pregnancy. Comparable as a technology-forward entrant addressing maternal/fetal monitoring with a different modality (wearable vs. transvaginal sensor).
- Bloomlife: Digital health company developing connected maternal-fetal monitoring solutions for prenatal and intrapartum use. Comparable as a venture-backed emerging player targeting the same maternal-health monitoring category Raydiant addresses.
Regional players
- Edan Instruments: China-based manufacturer of patient and fetal monitoring devices sold across Asia, EMEA, and other markets. Comparable as a fetal/patient monitor OEM competing for the same hospital capital equipment budgets in non-US geographies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Raydiant Oximetry social profiles
Digital presenceRaydiant Oximetry compliance and trust
Trust signalCompliance1 record
Raydiant Oximetry financial estimates
Financial estimateRevenue estimate
Valuation estimate
Raydiant Oximetry leadership team
Management profileNumber of profiles
Profiles20 records
Raydiant Oximetry funding detail
Funding detailFunding overview
Funding rounds11 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Raydiant Oximetry M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Raydiant Oximetry
What does Raydiant Oximetry do?
Raydiant Oximetry is a clinical-stage medical device company developing Lumerah, a non-invasive fetal pulse oximeter that directly measures fetal oxygen saturation levels during active labor via an investigational transvaginal sensor placed on the fetus's cheek. The technology is designed for obstetrical providers and labor & delivery units in hospitals to reduce unnecessary cesarean deliveries and improve maternal and neonatal outcomes. Once FDA approval is obtained, the company plans to sell the Lumerah device and related consumables to hospitals and healthcare systems globally.
Is Raydiant Oximetry a public or private company?
Raydiant Oximetry is a private company. It is classified as venture growth investor backed and is currently operating.
When was Raydiant Oximetry founded?
Raydiant Oximetry was founded in 2019. It employs 11 to 50 people.
Where is Raydiant Oximetry based?
Raydiant Oximetry is headquartered in San Ramon, United States, in the North America region.
How does Raydiant Oximetry make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are potential Licensing.
Who are Raydiant Oximetry's main competitors?
Broad incumbents on record are GE HealthCare, Philips (Avalon Fetal Monitors), Masimo and Medtronic. Direct peers are Neoventa Medical, PeriGen and Huntleigh Healthcare. Emerging players are Nuvo Group (Invu platform) and Bloomlife. Edan Instruments is listed as a regional player.
Does Raydiant Oximetry have an API?
No public API is recorded for Raydiant Oximetry.
What industry is Raydiant Oximetry in?
Raydiant Oximetry's product category is Fetal Monitoring Medical Devices. Its primary akta.pro industry code is HLAHACAF, Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables), with a secondary code of HLACAPAG, Maternal, Neonatal & Pediatric Remote Monitoring. Its NAICS code is 334510 and its SIC code is 3845.